Language selection

Search

Patent 1095518 Summary

Third-party information liability

Some of the information on this Web page has been provided by external sources. The Government of Canada is not responsible for the accuracy, reliability or currency of the information supplied by external sources. Users wishing to rely upon this information should consult directly with the source of the information. Content provided by external sources is not subject to official languages, privacy and accessibility requirements.

Claims and Abstract availability

Any discrepancies in the text and image of the Claims and Abstract are due to differing posting times. Text of the Claims and Abstract are posted:

  • At the time the application is open to public inspection;
  • At the time of issue of the patent (grant).
(12) Patent: (11) CA 1095518
(21) Application Number: 1095518
(54) English Title: PYRANO-AS-TRIAZINES
(54) French Title: PYRANO-AS-TRIAZINES
Status: Term Expired - Post Grant
Bibliographic Data
(51) International Patent Classification (IPC):
  • C07D 49/04 (2006.01)
  • C07D 49/08 (2006.01)
(72) Inventors :
  • BENNETT, GREGORY B. (United States of America)
(73) Owners :
  • SANDOZ LTD.
(71) Applicants :
  • SANDOZ LTD. (Switzerland)
(74) Agent: KIRBY EADES GALE BAKER
(74) Associate agent:
(45) Issued: 1981-02-10
(22) Filed Date: 1978-03-16
Availability of licence: N/A
Dedicated to the Public: N/A
(25) Language of filing: English

Patent Cooperation Treaty (PCT): No

(30) Application Priority Data:
Application No. Country/Territory Date
779,071 (United States of America) 1977-03-18

Abstracts

English Abstract


600-6781
CANADA
IMPROVEMENTS IN OR RELATING TO ORGANIC COMPOUNDS
Abstract of the Disclosure
This disclosure describes novel compounds of the
formula
<IMG>
wherein R1 and R2 each independently represent hydrogen,
fluorine, chlorine, alkyl of 1 to 4
carbon atoms, straight chain alkoxy
of 1 to 4 carbon atoms, amino, nitro
or trifluoromethyl, and
X represents <IMG> or <IMG>,
which are useful as minor tranquilizers and sleep inducers.


Claims

Note: Claims are shown in the official language in which they were submitted.


The embodiments of the invention in which an exclusive
property or privilege is claimed are defined as follows:
1. A process for the production of a compound of
formula I,
<IMG> (I)
in which x signifies <IMG> or <IMG>
and R1 and R2, which may be the same or
different, each signifies hydrogen,
fluorine, chlorine, alkyl of 1 to 4
carbon atoms, straight chain alkoxy of
1 to 4 carbon atoms, amino, nitro or
trifluoromethyl,
provided that (i) when one of R1 and R2 is nitro,
the other is other than nitro or
trifluoromethyl,
and (ii) when one of R1 and R2 is t-butyl or
trifluoromethyl, the other is other
than trifluoromethyl on an adjacent
carbon atom or t-butyl on an adjacent
carbon atom,
or a pharmaceutically acceptable acid addition salt
thereof, which comprises
a) producing a compound of formula Ia,
13

<IMG> Ia
in which R1 and R2 are as defined above, by
reacting the compound of formula II,
<IMG> II
with a compound of formula III
<IMG> III
in which R1 and R2 are as defined above,
and R3 is methyl or ethyl,
in an inert organic solvent and under an inert atmosphere
or b) producing a compound of formula Iaa,
<IMG> Iaa
14

in which R1 signifies hydrogen, fluorine,
chlorine, alkyl of 1 to 4 carbon atoms,
straight chain alkoxy of 1 to 4 carbon
atoms, or amino,
by nitrating a compound of formula Iab,
<IMG> Iab
in which R1 is as defined above,
in an inert organic solvent,
or c) producing a compound of formula Ib,
<IMG> Ib
in which R1 and R2 are as defined above, by
reacting a compound of formula Ia, stated above, with
cyclohexene in the presence of a noble metal catalyst, in
an inert organic solvent and under an inert atmosphere and
where necessary converting the resulting compound of the
formula I thus obtained into a pharmaceutically acceptable
acid addition salt thereof.

- 16 -
2. A compound of formula I, stated in Claim 1, or a
pharmaceutically acceptable salt thereof, whenever
prepared by a process according to Claim 1.
3. A process according to Claim 1 wherein R1 is
m-CF3, R2 is hydrogen, and X is <IMG>.
4. 3-(m-trifluoromethylphenyl)-5,8-dihydro-6,6,8-
trimethyl-5,8-ethano-6H-pyrano[4,3-e]-as-triazine-4-oxide
of the formula
<IMG>
or a pharmaceutically acceptable salt thereof, whenever
prepared by a process as claimed in Claim 3 or by an
obvious chemical equivalent thereof.
5. A process according to Claim 1, wherein R1 is
m-NO2, R2 is hydrogen and X is <IMG> .
6. 3-(m-nitrophenyl)-5,8-dihydro-6,6,8-trimethyl-5,8-
ethano-6H-pyrano[4,3-c]-as-triazine of the formula
<IMG>
or a pharmaceutically acceptable salt thereof, whenever
prepared by a process as claimed in Claim 5 or by an
obvious chemical equivalent thereof.
16

Description

Note: Descriptions are shown in the official language in which they were submitted.


Case 600-6781
~s~si~
IMPROVl~MENTS IN OR RELATI~G TO Ol-~GANIC COMPOUNDS
This invention relates to 5,8-dihydro-6,6,8-trimethyl-
5,8-ethano-6H-pyrano r4 ~ 3-e]-as-triazines and their 4-oxides.
- More particularly, this invention provides compounds
of formula I,
~3
H3C ~ X ~ (I~
C~3 ~ Rl
R2 :' :" ' '' ' ' ''-
in ~hich X signifies ~ N ~ or ~N~
and Rl and R2, which may be the same or
different, each signifies hydrogen,
fluorine, chlorine, alkyl of l to 4
carbon atoms, straight chain alkoxy of
l to 4 carbon atoms, aminor nitro or
trifluoromethyl,
provided that (i) when one of Rl and R2 is nitrol the :
other is other than nitro or
lS trifluoromethyl,
and (ii) when one of Rl and R2 is t-butyl
: or trifluoromethyl, the other is
other than trifluoromethyl on an
adjacent carbon atom or t-butyl on
. . -

~9~
- 2 - 600-67~1
an adjacent carbon atom.
The invention also provides processes for the
production of compounds of formula I, characterised by
a) producing a compound of formula Ia,
~2
. . - . -
5in which Rl and R2 are as defined above,
by reactiny the compound of formula II,
0 ~ r~_~ 2 II
CH3
with a compound of formula III
Rl
~ ~ C(OR3)3 III
R2
in which Rl and R2 are as defined above,
. and R3 is methyl or ethyl,
in an inert organic solvent and under an inert atmosphere ,
.

1~99~8
- 3 - 600 6781
b) producing a compound of formula Iaa,
3C ~ ~ 1 Iaa
N02
in which Rl signifies hydrogen, fluorlne, chlorine,
alkyl of 1 to 4 carbon atoms, straight
chain alkoxy of 1 to 4 carbon atoms,
or amino,
by nitrating a compound of formula Iab,
3 ~ I ~ , Iab
in which Rl us as defined above,
in an inert organic solvent,
or c) producing a compound of formula Ib,
H3C I ~ , ~ Ib

9~
- 4 - 600-6781
in which Rl and R2 are as defined above,
by reacting a compound of formula Ia, stated above, with
cyclohexene in the presence of a noble metal catalyst, in
an inert organic solvent and under an inert atmosphere.
Process a) is suitably effected at a temperature
of from 70 to 200C, preferably 130 to 150C, and the
reaction time may, for example, vary from 12 to 36 hours,
more typically 15 to 20 hours. Suitable solvents include
aromatic hydrocarbons, such as benzene or toluene, and
lower alkanols, such as methanol or ethanol. Alternat-
ively and preferably, an excess of the compound of formula
III may he employed to provide a reaction medium. The
inert atmosphere may, for example, be helium, argon or,
preferably, nitrogen.
Process b) is a conventional aromatic nitration
process which may be effected using conventional nitron-
ium ion-forming reagents, including a mixture of sulphuric
and nitric acid, a mixture of trifluoromethanesulphonic
acid and fuming nitric acid, or a mixture of hydrogen
fluoride and dinitrogen peroxide in nitromethane at -20~C
saturated with boron trifluoride. The preferred reagent
is a mixture of trifluoromethanesulphonic acid and
fuming nitric acid, preferably in a molar ratio of 2:1.
Suitable solvents include aromatic hydrocarbons, such as
methylene chloride or chloroform, preferably methylene
chloride. The reaction temperature is suitably from -80

S5~L~
5 - 600-6781
to +70C, preferably -35 to ~35C and the reaction
time may, for example, vary from 19 to 96 hours, more
usually 60 to 75 hours.
In process c), the noble metal catalyst is suitably
platinum, rhodium or, preferably, palladium, either neat
or on a support, such as charcoal. The process is then
conveniently effected at a temperature of from 20 to
200C, preferably 70 to 110C and the reaction time may
vary, for example from 5 to 72 hours, more ususally from
15 to 30 hours. Suitable solvents include lower alkanols,
such as methanol or ethanol, preferably the latter.
Process c) is effected under an inert atmosphere such as
helium, argon or, preferably, nitrogen.
The resulting compounds of formula I may be isolated
and purified using conventional techniques. Where required,
free base forms thereof may be converted into acid addition
salt forms in conventional manner and vice versa.
The compound of formula II may be prepared by treatiny
the compound of formula IV with hydrazine according to the
following reaction scheme:
CH3 CH3
3 ~ ~ N284 C8 ~OH
CH3 3
I
¦ IV (II)
.. ~ .

;~95S~L~
- 6 - 600-6781
The reaction is suitably effected at a temperature
of from 0 to 150C, preferably 75 to 85C, in an inert
organic solvent, for example a lower alkanol, preferably
ethanol, and under an inert atmosphere. The reaction time
S may vary from 1 to 18 hours, more usually 2 to 8 hours.
The compounds of formulae III and IV are either
known or may be produced in conventional manner from
available materials.
The compounds of formula I possess phannacological
activity. In particular, they possess sleep-inducing
and minor tranquillising activity, as indicated
- 1) by the hexobarbital reinduction method of Winter,
J. Pharmacol. and Exp. Therap. 94, 7-11 (1948); 2) in
the Cebus monkey using chronically implanted elect-
rodes. Brain readings are obtained via a ten or sixteen
channel electroencephalograph. For the recording sessions,
the monkeys are restrained by neck and waist plates in
chairs in full side observation cages, at the same time
every night, for thirteen and one half hours, Monday
through Thursday. Gross behavior is monitored via
closed circuit television and video tape recordings.
The compound of formula I is administered p.o. immedi-
ately on placing the monkey in the observation cages
with at least seven days intervening between drug
administration. Physiological saline is administered
via a similar route and at the same time on all control
. .
, .

~9~
- 7 - ~00-6781
runs. Control data are collected at least three days
per wec]c and accumulated to yive control data for fif-
teen sessions per monkey. Data from each session are
statistically compared via computer analysis to the
previous 5-15 control sessions for the particular animal,
with particular emphasis being given to the following
phases of the sleep-wakefulness cycle: resting awake, light
sleep, deep sleep, paradoxical (P~EM) sleep, "pseudo-"
paradoxical sleep, latency to onset of deep sleep, and
latency to onset of first epoch of paradoxical sleep;
3) by their ability to produce docility in behaviour
tests in mice given 25 to 200 mg/kg of animal body
weight, i.p., of the test compound according to the 30-
word adjective check sheet system basically as deserihed
by Irwin S. (Gordon Research Conferenee, Medieinal
Chemistry, 1959) and Chen (Symposium on Sedative and
Hypnotie drugs, Willians and Wilkins, 1954);
4) by their ability to antagonize chronic convulsions
and death in miee given 20-250 mg/kg i.p. of the test
eompound ~0 minutes prior to administration of 50 mg/kg
i.p. of N-sulfamoylazepine;
5) by scoring for loss of righting reflex aeeording to
the method of Reed-Muench [American Journal of Hygiene
27, 493-497, (1938)], in whieh mice are administered
12.5 mg/kg, i.p. of Thioridazine, immediately after
whieh the test eompound is administered at dosages of 5
to 100 mg/kg in a volume of 0.1 ml/10 g body weight.
,
~ . ,

:;1 09S5i&3
- 8 - 600-67~1
Sixty minutes after dosing, the mice are scored for loss
of righting reflex, and
6) by their ability to reduce conflicts as defined in
the Geller Conflict Test [Irving Geller, Psychopharma-
cologia, I, 42-492, (1960)].
The compounds are therefore indicated for use as
sleep inducers and minor tranquillisers. For sleep
inducing usage, an indicated suitable daily dosage is
from 1 to 300 mg, suitably given as a single dosage
at bedtime. For minor tranquillisin~ usage, an indicated
suitable daily dosage is from 5 to 500 mg, suitably
administered in divided dosages of from 1.25 to 250 mg,
two to four times daily or in retard form.
The compounds may be admixed with conventional
pharmaceutically acceptable diluents or carriers and,
optionally, other excipients, and administered in such
forms as tablets or capsules.
The compounds may be employed in free base form
or in the form of pharmaceutically acceptable acid
addition salts, which salt forms possess the same order
of activity as the free base forms. Suitable acids for
salt formation include mineral acids, such as hydrochloric,
hydrobromic and sulphuric acid, and organic acids, such as
succinic, benzoic and maleic acid.
The preferred compounds of formula I are those
in which Rl is NO2 or CF3, preferably in the m-position,
and R2 is hydrogen.
The following Examples illustrate the invention:

1095~18
- 9 - 600-6781
EX~MPLE 1: 3-Ph~enyl-5,8-dihy~ro-6,6,8-trimethy~--5!8-
ethano-6H- rano[4 3 e-]-as'-tri'azine-4-oxide.
[process a)] -
(i~ 1,3,3-Trimethyl-2-oxabicyclo[2,2,2~octan-5,6-dione-
___ _________ __________ ___._______________________
5-oxime-6-hydrazone (com~ound of formula II)
A mixture of 1.97 g (0.01 mole~ 1,3,3-trimethyl-
2-oxabicyclo~2,2,2]octan-5,6-dione-5~oxime and 0.35 ml
(0.011 mole) anhydrous hydrazine (98~) in 25 ml
absolute ethanol is refluxed under nitrogen at a bath
temperature of 80C for 1 hour. After evaporation of
the solvent, the residue is recrystallized from ether
to give 1,3,3-trimethyl-2-oxabicyclo[2,2,2]octan-
5,6-dione-5-oxime-6-hydrazone; m.p. 138 to 142C.
(ii) 3-Phenyl-5L8-dihydro-6L6 8-trimethyl-5,8-ethano-
_._ ____ _ __ _ __ __ __ _ _ _L____ ____ _ ___ ____ __ __
6H-~yrano[4,3-el-as-triazine-4-oxide (com~ound of
formula Ia)
___________,
A solution of 2.11 g (0.01 mole) 1.3.3-trimethyl-
2-oxabicyclo[2,2,2]octan-5,6-dione-5-oxime-6-hydrazone
in 10 ml trimethylorthobenzoate is refluxed under
nitrogen for 18 hours at a bath temperature of 140C
during which time all distillate is removed. The
resulting mixture is cooled and evaporated to dryness
in vacuo. After filtering the residue,dissolved in ~-
- 2% methanol-chloroform,through silica gel, and
evaporation of the filtrate the resulting solid is
.
.

~09~;S18
- 10 - 600-6781
triturated with ether,giving 3-phenyl-5,8-dihydro-
6,6,8-trimethyl-5,8-ethano-6H-pyrano[4,3-e]-as-
triazine-4-oxide; m.p. 186.5 to 189C.
EXA~lPLE 2- 3-(m-nitrophenyl)-5,8-dih~dro-6,6,8-trimethyl-
5,8-ethano-6H-p~yrano[4!-3--e]-as-triazine-4-oxide.
[process b)]
To a mixture of 0.2 ml (0.005 mole) fuming nitric
acid and 1.5 g (0.01 mole) trifluoromethanesulfonic acid in
15 ml anhydrous methylene chloride maintained at a tempera-
ture of -30C there is added dropwise a solution of 0.60 g
(0.002 mole) 3-phenyl-5,8-dihydro-6,6,8-trimethyl-5,8-ethano-
6H-pyrano[4,3-e]-as-triazine-4-oxide in 15 ml methylene
chloride, maintaining the temperature at -30C throughout
the addition. The resulting mixture is stirred at ambient
temperature for 72 hours, then poured onto ice and
neutralized with solid sodium bicarbonate. The oryanic layer
is removed, washed with saturated brine solution, dried over
magnesium sulfate and evaporated. Trituration of the resul-
ting residue with ether gives 3-~m-nitrophenyl)-5,8-dihydro-
6,6,8-trimethyl-5,8-ethano-6H-pyrano[4,3-e]-as-triazine-4-
oxide~monohydrate; m.p. 150C (decomposes).
EXAMPLE 3: 3-Phen~1-5,8-dihydro-6,6,8-trimethyl- ~ ethano-
. . _
6H-pyrano[4,3-e]-as-triaz~ine [process c)]
To a solution of 1.80 y (0.006 mole) 3-phenyl-5,8-
dihydro-6,6,8-trimethyl~5,8-ethano-6H-pyrano[4,3-e]-as-

~o?s5~
11 - 600-67~31
triazine-4-oxide and 1.50 g (0.018 mole) cyclohexene in
30 ml absolute ethanol there is added 60 mg 10~ palladium
on charcoal. The resulting mixture is refluxed under a
nitrogen atmosphere for 18 hours. The catalyst is then
removed by filtration and the filtrate evaporated to give
3-phenyl-5,8-dihydro-6,6,8-trimethyl-5,8-ethano-6IJ-pyrano
[4,3-e]-as-triazine; m.p. 180 to 189C.
Further compounds of formula I, in which X, Rl and
R2 have the significances indicated in the following
table,may be prepared in manner analogous to the indicated
Example(s) using appropriate starting materials in
approximately equivalent amounts.
.

~S~l~
12 - 600 6781
.. _ _ I __ .. _ ._ ~ _ . ,
Ex. ~nalogy to Process X Rl R2 m-p- C
No. Ex. No.
.. .. _ ~ ._. .. _ ...
4 1 a N~ O p-Cl H
1 a ~ p-F H 157-158
6 1 a l~ p-CH3 H 177-178
7 1 a ~l p-OCH3 H 148-149
8 1 a ., m-CF3 H 157.5-158.5
9 1 a ~ p-NH2 H . - - .
10 1 a - P-N02 H
11 1 a ~ m-N02 H
12 1 a ~ m-Cl H 180
13 1 a ~ m-OCH3 p-OCH3
14 2 b ~ m-N02p-CH3
15 2 b ~ m-N02p-OCH3133-135
16 3 c N p-C1 H
17 3 e ~ p-F H
18 3 c ~ p-CH3 H
19 3 c ~ p-OCH3 H
20 3 e ~ m-CF3 H235-250 (dec.)
21 3 e ~ p-NH2 H
22.3 e - P-N02 H
23 3 e ~ m-N02 H300 (dec.)
24 3 c ~ m-Cl H
25 3 c ~ m-OCH3 p-OCH3
. _ ~ . L _
.

Representative Drawing

Sorry, the representative drawing for patent document number 1095518 was not found.

Administrative Status

2024-08-01:As part of the Next Generation Patents (NGP) transition, the Canadian Patents Database (CPD) now contains a more detailed Event History, which replicates the Event Log of our new back-office solution.

Please note that "Inactive:" events refers to events no longer in use in our new back-office solution.

For a clearer understanding of the status of the application/patent presented on this page, the site Disclaimer , as well as the definitions for Patent , Event History , Maintenance Fee  and Payment History  should be consulted.

Event History

Description Date
Inactive: IPC from MCD 2006-03-11
Inactive: Expired (old Act Patent) latest possible expiry date 1998-02-10
Grant by Issuance 1981-02-10

Abandonment History

There is no abandonment history.

Owners on Record

Note: Records showing the ownership history in alphabetical order.

Current Owners on Record
SANDOZ LTD.
Past Owners on Record
GREGORY B. BENNETT
Past Owners that do not appear in the "Owners on Record" listing will appear in other documentation within the application.
Documents

To view selected files, please enter reCAPTCHA code :



To view images, click a link in the Document Description column. To download the documents, select one or more checkboxes in the first column and then click the "Download Selected in PDF format (Zip Archive)" or the "Download Selected as Single PDF" button.

List of published and non-published patent-specific documents on the CPD .

If you have any difficulty accessing content, you can call the Client Service Centre at 1-866-997-1936 or send them an e-mail at CIPO Client Service Centre.


Document
Description 
Date
(yyyy-mm-dd) 
Number of pages   Size of Image (KB) 
Claims 1994-03-08 4 76
Abstract 1994-03-08 1 14
Drawings 1994-03-08 1 7
Descriptions 1994-03-08 12 314